115 related articles for article (PubMed ID: 1619922)
1. Lymphocyte migration to tumors after hyperthermia and immunotherapy.
Midis GP; Fabian DF; Lefor AT
J Surg Res; 1992 May; 52(5):530-6. PubMed ID: 1619922
[TBL] [Abstract][Full Text] [Related]
2. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
Basse PH
APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
[TBL] [Abstract][Full Text] [Related]
3. Local hyperthermia abrogates the anti-immunotherapeutic effect of interleukin-8.
Geehan DM; Fabian DF; Lefor AT
J Surg Oncol; 1994 Jun; 56(2):102-6. PubMed ID: 8007673
[TBL] [Abstract][Full Text] [Related]
4. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
Wakizaka Y
Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals.
Kjaergaard J; Hokland ME; Agger R; Skovbo A; Nannmark U; Basse PH
Cancer Immunol Immunother; 2000 Jan; 48(10):550-60. PubMed ID: 10630307
[TBL] [Abstract][Full Text] [Related]
6. In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats.
Felgar RE; Hiserodt JC
Cell Immunol; 1990 Sep; 129(2):288-98. PubMed ID: 2383892
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of a new interleukin-2 slow delivery system on methylcholanthrene-induced fibrosarcoma in mice.
Fujiwara T; Sakagami K; Orita K
J Cancer Res Clin Oncol; 1990; 116(2):141-8. PubMed ID: 2324156
[TBL] [Abstract][Full Text] [Related]
8. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
9. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
Saarloos MN; Khoo NK; Lala PK
Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor alpha mediates the antitumor effect of combined interleukin-2 and whole body hyperthermia.
Fritz KL; Koziol S; Fabian DF; Lefor AT
J Surg Res; 1996 Jan; 60(1):55-60. PubMed ID: 8592432
[TBL] [Abstract][Full Text] [Related]
11. Combined hyperthermia and immunotherapy treatment of multiple pulmonary metastases in mice.
Strauch ED; Fabian DF; Turner J; Lefor AT
Surg Oncol; 1994 Feb; 3(1):45-52. PubMed ID: 8186870
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
13. Enhanced survival of IFN-alpha augmented IL-2 therapy of pulmonary metastases: efficacy comparable to interleukin-2 and lymphokine activated killer cells.
Kim B; Warnaka P
J Surg Res; 1991 Jan; 50(1):40-6. PubMed ID: 1987429
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
Tjota A; Zhang YQ; Piedmonte MR; Lee CL
J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer (LAK) cells can be focused at sites of tumor growth by products of macrophage activation.
Migliori RJ; Gruber SA; Sawyer MD; Hoffman R; Ochoa A; Bach FH; Simmons RL
Surgery; 1987 Aug; 102(2):155-62. PubMed ID: 3497459
[TBL] [Abstract][Full Text] [Related]
16. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
[TBL] [Abstract][Full Text] [Related]
17. Augmented accumulation of transferred lymphokine-activated killer (LAK) cells at murine tumor sites through production of LAK-attractant facilitated by chemotherapy.
Hosokawa M; Wakizaka Y; Kuramitsu Y; Micallef M; Togashi Y; Kobayashi H
Tohoku J Exp Med; 1992 Oct; 168(2):413-6. PubMed ID: 1306328
[TBL] [Abstract][Full Text] [Related]
18. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
19. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
Kedar E; Ben-Aziz R; Shiloni E
Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
[TBL] [Abstract][Full Text] [Related]
20. [Combined effect of adoptive immunotherapy (AIT) with lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) and chemotherapy in tumor-bearing mice].
Yamano Y; Yoshimura A; Shibuya M; Kudoh S
Nihon Ika Daigaku Zasshi; 1997 Jun; 64(3):211-9. PubMed ID: 9217363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
